Oncology Clinical Trials Market Size, Share, Growth, Trends, Company Analysis, Regional Insights and Forecast 2020 - 2027

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Oncology Clinical Trials Market, By Phase

7.1.  Oncology Clinical Trials Market, By Phase Type, 2020-2030

7.1.1.    Phase I

7.1.1.1.        Market Revenue and Forecast (2016-2030)

7.1.2.    Phase II

7.1.2.1.        Market Revenue and Forecast (2016-2030)

7.1.3.    Phase III

7.1.3.1.        Market Revenue and Forecast (2016-2030)

7.1.4.    Phase IV

7.1.4.1.        Market Revenue and Forecast (2016-2030)

Chapter 8.  Global Oncology Clinical Trials Market, By Study Design

8.1.  Oncology Clinical Trials Market, By Study Design, 2020-2030

8.1.1.    Interventional

8.1.1.1.        Market Revenue and Forecast (2016-2030)

8.1.2.    Observational

8.1.2.1.        Market Revenue and Forecast (2016-2030)

8.1.3.    Expanded Access

8.1.3.1.        Market Revenue and Forecast (2016-2030)

Chapter 9.  Global Oncology Clinical Trials Market, By Cancer Type

9.1.  Oncology Clinical Trials Market, By Cancer Type, 2020-2030

9.1.1.    Lung cancer

9.1.1.1.        Market Revenue and Forecast (2016-2030)

9.1.2.    Breast cancer

9.1.2.1.        Market Revenue and Forecast (2016-2030)

9.1.3.    Thyroid cancer

9.1.3.1.        Market Revenue and Forecast (2016-2030)

9.1.4.    Leukemia

9.1.4.1.        Market Revenue and Forecast (2016-2030)

9.1.5.    Liver cancer

9.1.5.1.        Market Revenue and Forecast (2016-2030)

9.1.6.    Skin cancer

9.1.6.1.        Market Revenue and Forecast (2016-2030)

9.1.7.    Lymphoma

9.1.7.1.        Market Revenue and Forecast (2016-2030)

9.1.8.    Pancreatic cancer

9.1.8.1.        Market Revenue and Forecast (2016-2030)

9.1.9.    Prostate cancer

9.1.9.1.        Market Revenue and Forecast (2016-2030)

9.1.10.  Colon & rectal cancer

9.1.10.1.      Market Revenue and Forecast (2016-2030)

9.1.11.  Urinary system cancer

9.1.11.1.      Market Revenue and Forecast (2016-2030)

9.1.12.  Other cancer

9.1.12.1.      Market Revenue and Forecast (2016-2030)

Chapter 10.      Global Oncology Clinical Trials Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, By Phase (2016-2030)

10.1.2.  Market Revenue and Forecast, By Study Design (2016-2030)

10.1.3.  Market Revenue and Forecast, By Cancer Type (2016-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.1.4.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.1.4.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.1.5.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.1.5.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, By Phase (2016-2030)

10.2.2.  Market Revenue and Forecast, By Study Design (2016-2030)

10.2.3.  Market Revenue and Forecast, By Cancer Type (2016-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.2.4.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.2.4.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.2.5.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.2.5.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.2.6.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.2.6.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.2.7.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.2.7.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, By Phase (2016-2030)

10.3.2.  Market Revenue and Forecast, By Study Design (2016-2030)

10.3.3.  Market Revenue and Forecast, By Cancer Type (2016-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.3.4.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.3.4.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.3.5.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.3.5.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.3.6.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.3.6.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.3.7.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.3.7.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, By Phase (2016-2030)

10.4.2.  Market Revenue and Forecast, By Study Design (2016-2030)

10.4.3.  Market Revenue and Forecast, By Cancer Type (2016-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.4.4.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.4.4.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.4.5.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.4.5.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.4.6.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.4.6.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.4.7.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.4.7.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, By Phase (2016-2030)

10.5.2.  Market Revenue and Forecast, By Study Design (2016-2030)

10.5.3.  Market Revenue and Forecast, By Cancer Type (2016-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.5.4.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.5.4.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, By Phase (2016-2030)

10.5.5.2.      Market Revenue and Forecast, By Study Design (2016-2030)

10.5.5.3.      Market Revenue and Forecast, By Cancer Type (2016-2030)

Chapter 11.  Company Profiles

11.1.              IQVIA

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              PAREXEL International Corporation

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Pharmaceutical Product Development, LLC

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Charles River Laboratory

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              ICON Plc

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              PRA Health Sciences.

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Syneos Health

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Medpace

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Novotech

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Pivotal

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

Glossary of Terms